Investment Rating - The investment rating for iFlytek Medical Technology (2506.HK) is not explicitly stated in the provided report, but the overall sentiment appears positive based on the financial projections and growth expectations [1]. Core Insights - The company reported a revenue of approximately 915 million yuan for 2025, reflecting a year-on-year growth of 24.66%. The adjusted net profit was -39 million yuan, with an adjusted net profit margin of -4.3%, which is an improvement of about 1.8 percentage points year-on-year [1]. - The GBC (General Business Collaboration) model is expected to drive growth across various business segments, with significant contributions from grassroots solutions, regional solutions, hospital solutions, and patient management services [4]. - The company has made substantial progress in expanding its services, with the AI assistant covering 806 districts and counties, and the smart family doctor program rapidly expanding nationwide [4]. Financial Summary - For 2025, the company achieved total revenue of 915 million yuan, with projected revenues of 1.198 billion yuan in 2026, 1.479 billion yuan in 2027, and 1.834 billion yuan in 2028, representing growth rates of 31%, 23%, and 24% respectively [6]. - The adjusted net profit is expected to turn positive in 2026, with estimates of 4 million yuan, followed by 64 million yuan in 2027 and 111 million yuan in 2028, indicating significant growth rates of 106%, 1451%, and 74% respectively [7]. - The gross margin for 2025 was reported at 50.45%, with expectations for gradual improvement in subsequent years [6]. Business Segment Performance - Revenue from grassroots solutions was 263 million yuan (up 11% year-on-year), regional solutions generated 206 million yuan (up 34%), hospital solutions brought in 173 million yuan (up 31%), and patient management services accounted for 273 million yuan (up 29%) [4]. - The company’s comprehensive gross margin decreased by approximately 4.55 percentage points, primarily due to increased delivery costs and purchased products, but specific segments like hospital solutions and patient management services showed improvements in gross margins [4]. Future Projections - The company anticipates a gradual increase in gross margins, driven by the rollout of AI pilot projects and rapid growth in consumer-facing business [4]. - The financial outlook suggests a recovery in profitability, with a projected return on equity (ROE) of 0.46% in 2026, increasing to 10.30% by 2028 [6].

Investment Rating - The report maintains a "BUY" rating for Xunfei Healthcare, indicating potential returns of over 15% over the next 12 months [12]. Core Insights - Xunfei Healthcare reported FY25 revenue of RMB 915 million, reflecting a year-on-year growth of 24.7%, which was approximately 4% below estimates due to slower G-end growth in the second half of the year [1]. - The G-end growth decelerated significantly from 87% YoY in 1H25 to 4% YoY in 2H25, primarily due to centralized provincial procurement affecting project pricing [1]. - The B-end business showed robust recovery in 2H25, achieving a full-year growth of 31.1% YoY after a weaker first half [1]. - The attributable net loss narrowed by 51.1% YoY to RMB 65 million, driven by improved operating leverage [1]. - The company is focusing on solidifying its G-end leadership, accelerating B-end hospital penetration, and leveraging GBC synergy to develop C-end patient services as a long-term growth engine [1]. Financial Performance - Revenue projections for FY26E, FY27E, and FY28E are RMB 1,119 million, RMB 1,347 million, and RMB 1,599 million respectively, with YoY growth rates of 22.3%, 20.4%, and 18.7% [2]. - The attributable net profit is expected to improve from a loss of RMB 65 million in FY25 to a loss of RMB 40 million in FY26E, narrowing further to RMB 21 million in FY27E, and turning positive with a profit of RMB 3 million in FY28E [2]. - The earnings per share (EPS) is projected to improve from a loss of RMB 0.54 in FY25 to a loss of RMB 0.33 in FY26E, and finally to a profit of RMB 0.03 in FY28E [2]. Market Position and Strategy - Xunfei Healthcare has expanded its client base significantly, serving over 77,000 primary healthcare institutions and 600+ graded hospitals by the end of 2025 [1]. - The company achieved full coverage of its General Practice CDSS across all 90 counties in Zhejiang and secured its first out-of-province imaging cloud platform project in Guangxi [1]. - C-end patient management services revenue increased by 29% YoY to RMB 273 million, accounting for approximately 30% of total revenue, indicating a strategic shift towards a more recurring patient-paid business model [1]. - The communication conversion rate for paying patients reached 50% in 2025, with the Net Promoter Score (NPS) improving from 35% to 50% [1]. Valuation and Target Price - The target price for Xunfei Healthcare has been revised to HK$ 92.55, down from a previous target price of HK$ 143.59, reflecting a 33% upside from the current price of HK$ 69.60 [3]. - The target price is based on a price-to-sales (P/S) ratio of 9x for the 2026 estimates [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 修訂公司章程 訊飛醫療科技股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，董事會 已於董事會會議上審議及批准了（其中包括）《關於修改公司經營範圍暨修訂公 司章程的議案》。 (i) 本公司股東（「股東」）於本公司2025年年度股東會（「年度股東會」）上通過特 別決議案，以批准建議修改經營範圍及修訂公司章程（「公司章程」）；及 Xunfei Healthcare Technology Co., Ltd. 訊 飛 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2506） 建議修改公司經營範圍 建議修改公司經營範圍 及 根據本公司實際業務需要，董事會建議修改本公司的經營範圍。建議修改經營 範圍須滿足以下條件： | 條款序號 | 原表述 | 修改後表述 | | | | --- | --- | --- | --- | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Xunfei Healthcare Technology Co., Ltd. 訊 飛 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2506） 截至2025年12月31日止年度的年度業績公告 訊飛醫療科技股份有限公司（「本公司」、「公司」或「訊飛醫療」，連同其子公司， 統稱為「本集團」）董事（「董事」）會（「董事會」）謹此宣佈本集團截至2025年12月 31日止年度（「報告期」）的經審計合併業績。本公告符合香港聯合交易所有限 公司（「香港聯交所」）證券上市規則（「上市規則」）中有關年度業績初步公告附 載的資料之要求。該等年度業績已經本公司審計委員會（「審計委員會」）審閱。 財務摘要 截至12月31日止年度 | | 2025年 | 2024年 | 同比變動 | | --- | --- | --- | --- | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 訊 飛 醫 療 科 技 股 份 有 限 公 司 Xunfei Healthcare Technology Co., Ltd. 香港，2026年3月17日 截至本公告日期，本公司董事會包括：(i)執行董事陶曉東博士；(ii)非執行董事劉慶峰博士、 趙志偉先生及段大為先生；及(iii)獨立非執行董事汪揚教授、趙惠芳教授及談慶先生。 訊飛醫療科技股份有限公司（「本公司」，連同其子公司及合併聯屬實體，統稱 為「本集團」）董事會（「董事會」）茲通告謹定於2026年3月27日（星期五）舉行董事 會會議，以考慮及通過本集團截至2025年12月31日止的年度全年業績，建議之 末期股息（如有），以及處理其他事項。 承董事會命 訊飛醫療科技股份有限公司 執行董事 陶曉東博士 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2506） 董事會會議召開日期 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 非上市股份 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 43,581,121 RMB | | | 1 RMB | | 43,581,121 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 43,581,121 RMB | | | 1 RMB | | 43,581,121 | | 2. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | -- ...

Investment Rating - The report assigns a "Buy-A" investment rating to the company, with a target price of 105.54 HKD for the next six months [5][3]. Core Insights - The company is positioned as a leader in the AI medical sector, leveraging strong AI capabilities to maintain a high market share while actively entering new markets. The AI healthcare solutions market is projected to exceed 20 billion CNY by 2025 and 100 billion CNY by 2030, with a CAGR of 43.2% [1][3][36]. - The company has developed a comprehensive service model covering grassroots medical institutions, hospitals, and patients, supported by national policies that drive the AI medical industry [1][2][36]. - The company is expected to continue refining its core capabilities in AI medical models and expand its service offerings to patients, creating new revenue streams [3][2]. Summary by Sections 1. AI Medical Leader, Policy and Technology Driving Growth - The company is recognized as a leader in the AI medical field, providing a full range of services across grassroots medical institutions, hospitals, and patients [16][1]. - The company has achieved significant revenue growth, with a projected increase from 9.25 billion CNY in 2025 to 15.77 billion CNY in 2027, while narrowing net losses [9][3]. 2. Building Proprietary Large Models, Creating a Comprehensive AI Medical Technology System - The company has developed the "Spark Medical Model," which ranks first in MedBench evaluations and has clinical capabilities equivalent to attending physicians [1][2]. - Continuous upgrades to the AI model and collaboration with top hospitals enhance the reliability and commercial replicability of its technology [1][2]. 3. Policy-Driven Development of G-End, Constructing a Comprehensive Smart Medical System - The company has established a strong presence in 31 provinces and over 77,000 grassroots medical institutions, providing over 1.1 billion AI-assisted diagnostic suggestions [2][1]. - The company’s smart hospital solutions cover pre-diagnosis, diagnosis, and post-diagnosis stages, enhancing patient management and hospital service efficiency [2][1]. 4. Accelerating B-End Smart Hospital Construction, AI Empowering Competitive Advantages - The company is rapidly expanding its smart hospital framework, establishing a solid foundation for B-end business development [2][1]. - The dual focus on smart hospitals and AI assistants is driving the intelligent transformation of hospital services [2][1]. 5. Extending C-End Patient Services, Accelerating AI-Enabled Health Management Layout - The company is actively developing AI products for patients, enhancing personalized health management and follow-up services [2][1]. - The integration of AI in patient management is expected to create a closed-loop service model from doctors to patients, driving new growth [2][1]. 6. Profit Forecast and Investment Recommendations - The company is projected to achieve revenues of 9.25 billion CNY in 2025, 12.56 billion CNY in 2026, and 15.77 billion CNY in 2027, with a gradual improvement in profitability [9][3]. - The report emphasizes the potential for significant growth driven by policy support and technological advancements in the AI medical sector [3][1].

Core Viewpoint - Southbound funds have increased their holdings in iFlytek Medical Technology (02506.HK) by 26,000 shares on February 27, with a total net increase of 98,500 shares over the last five trading days and 120,600 shares over the last twenty trading days [1] Group 1: Southbound Fund Activity - Southbound funds have increased their holdings in iFlytek Medical Technology for three out of the last five trading days, resulting in a cumulative net increase of 98,500 shares [1] - Over the last twenty trading days, southbound funds have increased their holdings on eleven occasions, leading to a total net increase of 120,600 shares [1] - As of now, southbound funds hold 5,233,200 shares of iFlytek Medical Technology, which represents 6.76% of the company's total issued ordinary shares [1] Group 2: Company Overview - iFlytek Medical Technology Co., Ltd. primarily provides AI-enabled medical solutions in China [1] - The company's business lines include grassroots medical services, hospital services, patient services, and regional management platform solutions [1] - Key offerings include intelligent medical assistants, chronic disease management, smart hospital solutions, patient service management, imaging cloud platforms, and medical devices [1]

Group 1 - The core point of the article highlights that southbound funds reduced their holdings in iFlytek Medical Technology (02506.HK) by 4,000 shares on February 26 [1] - Over the past five trading days, there were three days of net increases in southbound fund holdings, totaling an increase of 85,800 shares [1] - In the last twenty trading days, there were ten days of net increases in southbound fund holdings, amounting to a total increase of 57,900 shares [1] Group 2 - As of now, southbound funds hold 5,207,200 shares of iFlytek Medical Technology, which represents 6.73% of the company's total issued ordinary shares [1] - iFlytek Medical Technology Co., Ltd. primarily provides AI-enabled medical solutions in China [1] - The company's business lines include grassroots medical services, hospital services, patient services, and regional management platform solutions [1]

Core Viewpoint - The article discusses the recent trading activity of iFlytek Medical Technology (02506.HK), highlighting the fluctuations in southbound capital holdings and the company's focus on AI-enabled healthcare solutions [1] Group 1: Southbound Capital Activity - On February 13, southbound capital increased its holdings in iFlytek Medical Technology by 19,500 shares [1] - Over the past five trading days, there were three days of net reductions, totaling 283,600 shares [1] - In the last 20 trading days, there were ten days of net increases, amounting to 40,700 shares [1] - Currently, southbound capital holds 5,154,200 shares of iFlytek Medical Technology, representing 6.66% of the company's issued ordinary shares [1] Group 2: Company Overview - iFlytek Medical Technology Co., Ltd. primarily provides AI-enabled healthcare solutions in China [1] - The company's business lines include grassroots medical services (intelligent medical assistants and chronic disease management), hospital services (smart hospital solutions and diagnostic assistants), and patient services (smart hospital patient services and post-discharge management) [1] - The company also offers regional management platform solutions, including smart health solutions and smart medical insurance [1] - iFlytek Medical Technology mainly operates in the domestic market [1]